US88165K1016
© Globe Newswire
26.12.2024
TVGN
LISTED
NASDAQ
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
News Preview
WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
TVGN
LISTED
NASDAQ
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annu...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2024
TVGN
LISTED
NASDAQ
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pion...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
10.12.2024
TVGN
LISTED
NASDAQ
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be atte...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.12.2024
TVGN
LISTED
NASDAQ
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
News Preview
WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, CEO of Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, Victor Sordillo PE,...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
News Preview
WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further e...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
News Preview
WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending Septembe...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
TVGN
LISTED
NASDAQ
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
News Preview
Key Takeaways:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
News Preview
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
News Preview
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
News Preview
WARREN, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shares details of its partnership with Microsoft (Nasdaq: MSFT) for St...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
News Preview
WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice f...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
29.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
News Preview
WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took significant steps toward expanding R&D and manufacturing capa...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
News Preview
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of th...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
News Preview
WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue f...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days
News Preview
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomen...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2024
TVGN
LISTED
NASDAQ
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days
News Preview
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
News Preview
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its oncology pipelin...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
News Preview
WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, elaborates on developing TVGN 920, a T cell therapy for the treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
TVGN
LISTED
NASDAQ
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
News Preview
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation f...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
News Preview
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
News Preview
WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to mee...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
News Preview
WARREN, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today reissues its previously announced topline results from its Proof...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
News Preview
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company’s ambition to address the Long COVID crisis as its...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
TVGN
LISTED
NASDAQ
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
News Preview
Tevogen Bio Reports Second Quarter 2024 Financial Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
News Preview
Tevogen Bio Reports Second Quarter 2024 Financial Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
TVGN
LISTED
NASDAQ
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
News Preview
Tevogen Bio congratulates Professor Sten Vermund, MD, PhD on being named as the dean of the USF Health College of Public Health....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
TVGN
LISTED
NASDAQ
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
News Preview
Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
News Preview
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter to stockholders highlighting recent achiev...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
TVGN
LISTED
NASDAQ
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
News Preview
WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise o...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
TVGN
LISTED
NASDAQ
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
News Preview
WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
News Preview
This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
News Preview
WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports publication of its phase I clinical trial data of TVGN 48...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
TVGN
LISTED
NASDAQ
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
News Preview
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
TVGN
LISTED
NASDAQ
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
News Preview
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
News Preview
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Reports First Quarter 2024 Financial Results
News Preview
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
News Preview
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
News Preview
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
TVGN
LISTED
NASDAQ
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
News Preview
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
